@article{23434,
  author = {Grobbee Diederick and Nozza Anna and Stähli Barbara and Schrieks Ilse and Malmberg Klas and Schwartz Gregory and A Lincoff Michael and Ryden Lars and Buse John and Henry Robert and Neal Bruce and Nicholls Stephen and Mellbin Linda and Svensson Anders and Wedel Hans and Weichert Arlette and Tardif Jean-Claude},
  title = {Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.},
  abstract = {<p><b>OBJECTIVE: </b>In observational cohorts, adiponectin is inversely associated and free fatty acids (FFAs) are directly associated with incident coronary heart disease (CHD). Adiponectin tends to be reduced and FFAs elevated in type 2 diabetes. We investigated relationships of adiponectin and FFA and major adverse cardiovascular events (MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 diabetes using data from the AleCardio (Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus) trial, which compared the PPAR-α/γ agonist aleglitazar with placebo.</p><p><b>RESEARCH DESIGN AND METHODS: </b>Using Cox regression adjusted for demographic, laboratory, and treatment variables, we determined associations of baseline adiponectin and FFAs, or the change in adiponectin and FFAs from baseline, with MACEs (cardiovascular death, myocardial infarction, or stroke) and death.</p><p><b>RESULTS: </b>A twofold higher baseline adiponectin ( = 6,998) was directly associated with risk of MACEs (hazard ratio [HR] 1.17 [95% CI 1.08-1.27]) and death (HR 1.53 [95% CI 1.35-1.73]). A doubling of adiponectin from baseline to month 3 ( = 6,325) was also associated with risk of death (HR 1.20 [95% CI 1.03-1.41]). Baseline FFAs ( = 7,038), but not change in FFAs from baseline ( = 6,365), were directly associated with greater risk of MACEs and death. There were no interactions with study treatment.</p><p><b>CONCLUSIONS: </b>In contrast to prior observational data for incident CHD, adiponectin is prospectively associated with MACEs and death in patients with type 2 diabetes and ACS, and an increase in adiponectin from baseline is directly related to death. These findings raise the possibility that adiponectin has different effects in patients with type 2 diabetes and ACS than in populations without prevalent cardiovascular disease. Consistent with prior data, FFAs are directly associated with adverse outcomes.</p>},
  year = {2018},
  journal = {Diabetes Care},
  volume = {41},
  pages = {1792-1800},
  issn = {1935-5548},
  doi = {10.2337/dc18-0158},
  language = {eng},
}